VYNE Therapeutics Inc. (VYNE)

VYNE Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	0.48	0.5	0.42	0.48	0.93	20.99
Revenue	0.48	0.5	0.42	0.48	0.93	20.99
Revenue Growth (YoY)	-2.06%	18.16%	-11.11%	-48.77%	-95.56%	4638.83%
Cost of Revenue	-	-	-	-	-	1.39
Gross Profit	0.48	0.5	0.42	0.48	0.93	19.6
Selling, General & Admin	12.14	13.19	13.38	16.39	20.3	89.54
Research & Development	30.94	30.95	16.31	18.39	19.54	43.53
Operating Expenses	43.08	44.14	29.68	34.77	39.84	133.08
Operating Income	-42.6	-43.64	-29.26	-34.3	-38.91	-113.48
Interest Expense	-	-	-	-	-5.61	-4.39
Interest & Investment Income	3.83	3.83	1.39	0.36	-	-
Other Non Operating Income (Expenses)	-1.05	-	-	-	-0.14	0.97
EBT Excluding Unusual Items	-39.82	-39.8	-27.87	-33.93	-44.66	-116.9
Impairment of Goodwill	-	-	-	-	-	-4.55
Gain (Loss) on Sale of Investments	-	-	-	-	-	0.14
Other Unusual Items	1.3	-	-	-	-	-84.73
Pretax Income	-38.52	-39.8	-27.87	-33.93	-44.66	-255.83
Income Tax Expense	0	0	-	0.01	-0.45	-0.26
Earnings From Continuing Operations	-38.52	-39.81	-27.87	-33.95	-44.21	-255.57
Earnings From Discontinued Operations	-0.02	-0.03	-0.58	10.74	-29.12	-
Net Income	-38.55	-39.83	-28.45	-23.21	-73.33	-255.57
Preferred Dividends & Other Adjustments	-	-	0.15	-	-	-
Net Income to Common	-38.55	-39.83	-28.6	-23.21	-73.33	-255.57
Shares Outstanding (Basic)	43	43	10	3	3	2
Shares Outstanding (Diluted)	43	43	10	3	3	2
Shares Change (YoY)	42.50%	314.57%	222.44%	11.44%	58.75%	282.06%
EPS (Basic)	-0.90	-0.94	-2.78	-7.28	-25.65	-141.90
EPS (Diluted)	-0.90	-0.94	-2.78	-7.28	-25.65	-141.90
Free Cash Flow	-39.89	-34.09	-25.34	-29.2	-56.37	-137.2
Free Cash Flow Per Share	-0.94	-0.80	-2.47	-9.16	-19.72	-76.18
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	93.37%
Operating Margin	-8949.37%	-8709.98%	-6900.47%	-7189.73%	-4179.48%	-540.54%
Profit Margin	-8097.69%	-7950.90%	-6745.52%	-4865.83%	-7876.37%	-1217.40%
Free Cash Flow Margin	-8380.25%	-6804.19%	-5976.65%	-6121.59%	-6054.46%	-653.53%
EBITDA	-	-43.63	-29.19	-34.22	-38.8	-113.13
D&A For EBITDA	-	0	0.07	0.07	0.11	0.34
EBIT	-42.6	-43.64	-29.26	-34.3	-38.91	-113.48
Revenue as Reported	0.48	0.5	0.42	0.48	0.93	20.99

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q